Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Lists
Only you see this
Abstract
The combination of ICI and SBRT has an acceptable safety profile and demonstrates a modest treatment benefit in patients with metastatic PDAC.
BibTeX
@inproceedings{xie2020immune,
author = {Changqing Xie and Austin G. Duffy and Gagandeep Brar and Suzanne Fioravanti and Donna Mabry‐Hrones and Melissa Walker and Cecilia Monge Bonilla and Bradford J. Wood and Deborah E. Citrin and Elizabeth M. Gil Ramirez and Freddy E. Escorcia and Bernadette Redd and Jonathan M. Hernandez and Jeremy L. Davis and Billel Gasmi and David E. Kleiner and Seth M. Steinberg and Jennifer Jones and Tim F. Greten},
title = {{Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma}},
booktitle = {Clinical},
year = {2020},
doi = {10.1158/1078-0432.ccr-19-3624},
}Loading related content...